Nascent Biotech, Inc. (NBIO)
Nascent Biotech, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in North Palm Beach, FL, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $34,443. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of 0.0%. Its beta of 1.76 implies it has historically moved more than the broad market.
Nascent Biotech, Inc., a clinical-stage biopharmaceutical firm, is committed to creating monoclonal antibody-based treatments for various forms of cancer. A primary focus is Pritumumab, a therapeutic currently in development to address aggressive brain malignancies such as glioblastoma and malignant astrocytoma. This drug also targets numerous epithelial cancers, including those affecting the lung, breast, colon, brain, and pancreas. Additionally, the company is advancing MultiPharm, its proprietary technology platform, which holds promise for applications in cancer therapy, diabetes, autoimmune disorders, and transplantation. The company's headquarters are situated in Vero Beach, Florida.
Nascent Biotech, Inc. is most often compared with the following Healthcare names: